HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?

HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?

Abstract Most patients with triple-negative breast cancer (TNBC) are not candidates for targeted therapy, leaving chemotherapy as the primary treatment option. Recently, immunotherapy has demonstrated promising results in TNBC, due to its immunogenicity. In addition, a novel antibody–drug conjugate,...

Full description

Bibliographic Details
Main Authors: Ximena Baez-Navarro, Nadine S. van den Ende, Anh H. Nguyen, Renata Sinke, Pieter Westenend, Johannes Bastiaan van Brakel, Claudia Stobbe, Johan Westerga, Carolien H. M. van Deurzen
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Breast Cancer Research
Subjects:
Triple-negative breast cancer
HER2-low
TILs
Neoadjuvant chemotherapy
Online Access:https://doi.org/10.1186/s13058-024-01783-z

Internet

https://doi.org/10.1186/s13058-024-01783-z

Similar Items